DOCSLIB.ORG

Thromboxane/Prostaglandin Endoperoxide Receptor Activation 'Mark 0

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thromboxane/Prostaglandin Endoperoxide Receptor Activation 'Mark 0 Br. J. Pharmacol. (1990), 99, 461-466 I--, Macmillan Press Ltd, 1990 Mediation of bradykinin-induced contraction in canine veins via thromboxane/prostaglandin endoperoxide receptor activation 'Mark 0. Aksoy, *Concetta Harakal, *J. Bryan Smith, Gwendolyn J. Stewart & Charles R. Zerweck Thrombosis Research Center and *Dept. of Pharmacology, Temple University School of Medicine, 3400 N. Broad St., Philadelphia, PA, 19140, U.S.A. 1 Canine jugular and femoral veins were studied to determine the possible importance of thromboxane (TXA2) and prostaglandin endoperoxides (prostaglandin H2, PGH2) in mediating bradykinin(BK)- induced contraction. 2 Isolated vein rings incubated in modified Krebs solution contracted to TXA2/PGH2 analogs SQ26655 and U44069 with potency of contraction exceeding that for BK. The potency ranking for both veins was SQ26655 > U44069 > BK > PGF21i> TXB2 > PGD2. 3 The cyclo-oxygenase inhibitors indomethacin (3 x 107M) and flufenamic acid (10- 5M) reduced BK contractions without affecting those induced by noradrenaline (NA). 4 TXA2/PGH2 receptor antagonists SQ29548 (10-8 M) and BM13177 (10-6 M) strongly inhibited BK- induced tension. The action of antagonists was reversible with negligible influence on NA-elicited contrac- tion. Selective removal of endothelium had no effect on BK-induced contraction or the action of the antagonists. 5 The thromboxane synthase inhibitors dazoxiben (10-4M) and CGS 12970 (10- M) had no significant inhibitory effect on BK-induced tension. 6 These results suggest that in canine jugular and femoral vein, the action of BK is largely dependent upon stimulation of the cyclo-oxygenase pathway to produce PGH2 and possibly TXA2, which can activate a smooth muscle TXA2/PGH2 receptor to elicit vasoconstriction. Introduction vasoconstriction associated with release of TXA2; this vaso- constriction can be reduced by the thromboxane synthase Bradykinin (BK) is a potent autacoid released during trauma, inhibitor OKY1581 (Kawasaki & Needleman, 1982). anaphylactic and other types of shock, and inflammatory The potential of PGH2 as an endogenous mediator of reactions. Although it can exert a hypotensive effect in vivo agonist-induced vasoconstriction is less well known, despite its due to arteriolar dilatation, BK has a predominantly con- ability to constrict vessels (Hamberg et al., 1975b; Goldberg et strictive action in many mammalian isolated veins (Tsuru et al., 1977; Coleman et al., 1981). A recent study has suggested al., 1976; Gaudreau et al., 1981). that prostaglandin endoperoxides can mediate arachidonic Evidence for endogenous prostaglandin synthesis along the acid-induced vasoconstriction in the rat perfused kidney cyclo-oxygenase pathway associated with BK-induced con- through the TXA2/PGH2 receptor, under conditions where traction has been obtained in several vascular preparations. TXA2 synthesis is inhibited (Quilley et al., 1989). However, the net vasoactive influence of the prostaglandins In this study, we show that the contractile action of BK on synthesized varies with species and vascular bed. Thus the 2 canine isolated vein preparations proceeds primarily cyclo-oxygenase inhibitors meclofenamate and indomethacin through activation of the cyclo-oxygenase pathway and sub- reduce contraction to BK in human foetal placental arteries sequent interaction of evoked PGH2 and possibly TXA2 with (Tulenko, 1981) and bovine mesenteric vein (Wong et al., the TXA2/PGH2 receptor. 1977) respectively, implying that a cyclo-oxygenase product mediates the contraction. Yet in rabbit ear vein (Crouch et al., 1981) and canine intestinal vasculature (Greenberg & Kado- Methods witz, 1982), indomethacin either has no effect or potentiates Dissection ofcanine veins the response to BK. Though BK can stimulate production of the vasoconstrictor Femoral and external jugular veins (4 vessels per dog) were prostaglandin F2. (PGF2e) in certain mesenteric veins (Wong carefully harvested from female mongrel dogs anaesthetized et al., 1977; Limas, 1977), few BK-related studies have been with sodium pentobarbitone (Nembutal, 25mgkg-1 animal done to determine the possible mediator role of the potent weight, injected into the cephalic vein). Supporting tissue was cyclo-oxygenase products thromboxane A2 (TXA2) and the carefully removed and side branches tied off, with care taken precursor prostaglandin endoperoxides (PGH2, PGG2) to maintain blood flow and not disturb the endothelial surface (Hamberg et al., 1975a), which interact with the thromboxane/ in the main vessels. The veins were then perfused with saline prostaglandin endoperoxide (TXA2/PGH2) receptor (Kennedy solution, ligated, excised and transferred to bicarbonate- et al., 1982; Saussy et al., 1985). Endogenous TXA2 can buffered physiological saline solution (PSS) at 40C. The dogs mediate vasoconstriction to acetylcholine in rabbit pulmonary were then killed by an intravenous injection of T-61. Veins artery (Altiere et al., 1986) and canine cerebral artery were stored with daily changes of PSS and were found to give (Shirahase et al., 1987), and to arachidonic acid in rabbit pul- consistent responses over a 3 day period. monary artery (Salzman et al., 1980) and intact rat kidney (Sakr & Dunham, 1982). In the perfused hydronephrotic In vitro setup and procedure rabbit kidney (a pathophysiological model), BK yields renal Circular ring segments 2.5 mm wide were cut perpendicular to 1 Author for correspondence. the vessel axis and were mounted with metal hooks and 462 M.O. AKSOY et al. jeweler's chains in individual tissue baths. Each bath was observations. Statistical significance was considered to occur equipped with (1) a micrometer gauge to measure and manip- when P < 0.05. ED50 values were derived by linear inter- ulate tissue length and (2) a Statham isometric force trans- polation of the normalized dose-response curves for a given ducer. This latter was connected through a signal amplifier agonist. and multiplexer to a Kipp and Zonen strip chart recorder. The mounted tissues were incubated in the baths with 50 ml volumes of PSS bubbled with 95% 02 - 5% CO2 at 370C, Results pH 7.4. The composition of the PSS was (mM): NaCl 127.4, KCl 4.7, MgSO4 7H20 1.2, KH2PO4 1.2, NaHCO3 16.0, Contractile responses ofcanine veins CaCl2 * 2H20 2.5, EDTA 0.04 and glucose 10.0. Each mounted vein segment was stretched in 0.4g increments at As shown in Figure 1, TXA2/PGH2 analogs SQ26655 and 15min intervals over a 90min period to a stable preload of U44069, along with PGF2a and BK, strongly contracted both 0.8g. vein preparations. The maximum responses for the latter 3 Concentration-response curves were obtained by the cumu- agonists were at least 55% of the maximum SQ26655 response lative addition of aliquots of agonist solutions. In a typical which was 3.77 + 0.40g (n = 15) for jugular and 2.17 + 0.22 g experiment, vein rings were assayed with BK to obtain a (n = 15) for femoral vein. In comparison, the maximum NA reproducible control response, then incubated with an antago- (10- M) response was 2.38 + 0.21 g (n = 40) for jugular, and nist or inhibitor for 30 min before re-assay with the agonist. 3.11 + 0.20 g (n = 37) for femoral vein. The ED50 values for the agonists in Figure 1 were: jugular-SQ26655: Removal ofendothelium 0.22 + 0.01 nM (n = 15), U44069: 1.70 + 0.03 nM (n = 8), BK: 17 + IM (n = 35), PGF2g: 159 + 5nM (n = 12); femoral- In some experiments, the endothelium was selectively removed SQ26655: 0.26 + 0.01 nm (n = 15), U44069: 2.23 + 0.05 nM from mounted jugular and femoral vein rings. The flattened (n = 10), BK: 55 + 2nM (n = 22), PGF2a,,: 501 + SnM(n = 17). end of a small wooden dowel was carefully rubbed several TXB2 contracted the veins only at concentrations exceeding times over the entire luminal surface of the ring which was 1O-6 M. PGD2 (10- 5 M) yielded negligible contractions in both then rinsed in PSS. Anatomically adjacent rings with undis- veins. In order of potency, these agents were ranked: SQ26655 turbed endothelium were used as controls. The presence or absence of endothelium was determined by scanning electron microscopy (SEM). After a set of experi- a ments, some vein rings were fixed in 1% glutaraldehyde while 120- mounted in the tissue baths, then removed for dehydration a) and critical-point drying. Samples were gold-coated and CD o 100- examined by SEM, which confirmed that the physical denu- a dation was effective in specifically removing endothelium. 0 SQ26655t LO 80- (15) LO Drugs used CD 60 Agonists used in this study were: noradrenaline-HCI (NA), (I) U444069 E prostaglandin D2 (PGD2) and thromboxane B2 (TXB2) (all E 40 / 4( from Sigma Chemical Co.); bradykinin (BK, Boehringer- E PG)F2,, TXB32 Ingelheim); prostaglandin F2g (dinoprost tromethamine, PGF2a; Upjohn Co.); U44069 ((15S)-hydro-9a,1la-(epoxyme- E 20 - PGD2 thano) prosta-5Z, 13E-dienoic acid; donated by Upjohn Co.) S ~~~~~~~~2(9) and SQ26655 ((lS-(la,2b(5Z),3a(1E,3s*),4a))-7-(3-(3-hydroxy-1- octenyl) - 7 - oxabicyclo(2.2.1)hept - 2 - yl)- 5 - heptenoic acid; 1 10 9 8 7 6 5 4 donated by Dr Ogletree, Squibb Research Inst.). Inhibitors -log [Agonist] (M) and antagonists included: indomethacin and flufenamic acid (Sigma Chemical Co.); SQ29548 ((1S4la,2b(5Z),3b,4a))-7-(3- ((2 - ((phenylamino)carbonyl) - hydrazino)methyl) - 7 - oxabicyclo b (2.2.1)hept-2-yl)-5-heptenoic acid; donated by Squibb 120 Research Inst.); BM13177 ((4-(2-benzenesulphonamido)-ethyl)- a) phenoxyacetic acid; donated by Dr Lefer, Thomas Jefferson 0 100- School of Medicine); CGS12970 (3-methyl-2(3-pyridyl)-1- a from Dr indoleoctanoic acid; gift Watthey, Ciba-Geigy, Inc.) o 80s SQ26655 and dazoxiben-HCl (4-(-2-(LH-imidazol-1-yl)ethoxy) benzoic O (15)U acid hydrochloride; donated by Dr Urquilla, Pfizer, Inc.). CD a 60 (0) Stock solutions of SQ26655, U44069, PGD2, TXB2, CO PGF21, SQ29548 and BM13177 were prepared in ethanol and stored E BK :3 40 (2 (17) at - 20°C.
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al
    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
    [Show full text]
  • Role of Proaggregatory and Antiaggregatory Prostaglandins in Hemostasis
    Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. P Gresele, … , G Pieters, J Vermylen J Clin Invest. 1987;80(5):1435-1445. https://doi.org/10.1172/JCI113223. Research Article Thromboxane synthase inhibition can lead to two opposing effects: accumulation of proaggregatory cyclic endoperoxides and increased formation of antiaggregatory PGI2 and PGD2. The elimination of the effects of the cyclic endoperoxides by an endoperoxide-thromboxane A2 receptor antagonist should enhance the inhibition of hemostasis by thromboxane synthase blockers. We have carried out a series of double-blind, placebo-controlled, crossover studies in healthy volunteers to check if this hypothesis may be operative in vivo in man. In a first study, in 10 healthy male volunteers, the combined administration of the thromboxane receptor antagonist BM 13.177 and the thromboxane synthase inhibitor dazoxiben gave stronger inhibition of platelet aggregation and prolonged the bleeding time more than either drug alone. In a second study, in 10 different healthy male volunteers, complete inhibition of cyclooxygenase with indomethacin reduced the prolongation of the bleeding time by the combination BM 13.177 plus dazoxiben. In a third study, in five volunteers, selective cumulative inhibition of platelet TXA2 synthesis by low-dose aspirin inhibited platelet aggregation and prolonged the bleeding time less than the combination BM 13.177 plus dazoxiben. In vitro, in
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • Acute Necrotizing Pancreatitis in Rats
    ACUTE NECROTIZING PANCREATITIS IN RATS Acute necrotizerende pancreatitis in ratten PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE GENEESKUNDE AAN DE ERASMUS UNIVERSITEIT ROTTERDAM OP GEZAG VAN DE RECTOR MAGNIFICUS PROF. DR. A.H.G. RINNOOY KAN EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN. DE OPENBARE VERDEDIGING ZAL PLAATSVINDEN OP VRIJDAG 22 JANUARI 1988 TE 15.45 UUR door BAAN VAN OOIJEN geboren te Rotterdam Druk: Krips Repro Meppel 1987 PROMOTIECOMMISSIE PROMOTOREN PROF. J.H.P. WILSON PROF. DR. J. JEEKEL OVERIGE LEDEN: PROF. DR. I.L. BONTA PROF. DR. J.L. TERPSTRA 1987 B. van Ooijen No part of this book may be reproduced in any form, by print, photoprint, microfilm or any other means without written permission from the publisher. De druk van dit proefschrift werd mede mogelijk gemaakt door financiele steun van het Bronovo Researchfonds. Wat heb ik dat ik niet gekregen heb? aJNTENTS page ABBREVIATIONS CHAPTER 1: INTRODUCTION AND AIM OF THE STUDY. 1 1.1. References 3 CHAPTH• 2: ETIOLOGICAL FACTORS IN ACUTE PANCREATITIS. 2. 1. Introduction 4 2.2. Etiological factors 5 2.2.1. Mechanical block at ampulla 6 a. Biliary tract disease 6 a-1. Bile reflux 7 a-2. Pancreatic duct obstruction 8 b. Obstruction at the level of the ampulla 8 b-1. Pancreas divisum 9 c. Duodenal disorders 9 2.2.2. Vascular factors and ischemia 9 2.2.3. Toxic and metabolic factors 10 a. Alcoholism 10 b. Hypercalcemia 11 c. Hypertriglyceridemia 12 d. Other metabolic causes 12 e. Drugs 12 2.2.4. Infection 13 2.2.5.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Pharmaceutical Appendix to the Harmonized Tariff Schedule
    Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States Basic Revision 3 (2021) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0286160 A1 Gilbert Et Al
    US 2010O286160A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0286160 A1 Gilbert et al. (43) Pub. Date: Nov. 11, 2010 (54) SUBSTITUTED PIPERAZINES AS CB1 Related U.S. Application Data ANTAGONSTS (60) Provisional application No. 60/946,896, filed on Jun. (75) Inventors: Eric J. Gilbert, Scotch Plains, NJ 28, 2007. (US); William J. Greenlee, Teaneck, NJ (US); Sarah Wei Li, Publication Classification Belle Mead, NJ (US); Michael W. (51) Int. Cl. Miller, Scotch Plains, NJ (US); A 6LX 3L/2197 (2006.01) Jack D. Scott, Scotch Plains, NJ C07D 24I/04 (2006.01) (US); Adrew Stamford, Chatham C07D 403/2 (2006.01) Township, NJ (US); Chander C07D 24I/02 (2006.01) Shekher Celly, Colonia, NJ (US) C07D 40/12 (2006.01) C07D 40/4 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) MERCK PATENT DEPARTMENT (K-6-1, 1990) (52) U.S. Cl. .................... 514/252.11:544/400: 544/372: 2000 GALLOPNGHILL ROAD 544/370; 544/357: 514/254.01: 514/254.05; KENILWORTH, NJ 07033-0530 (US) 514/252.12:544/360; 514/253.13:544/364; 514/253.09 (73) Assignee: Intervet Inc. (57) ABSTRACT (21) Appl. No.: 12/665,253 Compounds of Formula (I): or pharmaceutically acceptable (22) PCT Fled: Jun. 25, 2008 salts, Solvates, oresters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic (86) PCT NO.: PCT/US08/07917 syndrome and obesity, neuroinflammatory disorders, cogni tive disorders and psychosis, addiction (e.g., Smoking cessa S371 (c)(1), tion), gastrointestinal disorders, and cardiovascular condi (2), (4) Date: Jun.
    [Show full text]
  • Patent Application Publication (10) Pub. No.: US 2009/0131395 A1 Antonelli Et Al
    US 20090131395A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0131395 A1 Antonelli et al. (43) Pub. Date: May 21, 2009 (54) BIPHENYLAZETIDINONE CHOLESTEROL Publication Classification ABSORPTION INHIBITORS (51) Int. Cl. (75) Inventors: Stephen Antonelli, Lynn, MA A 6LX 3L/397 (2006.01) (US); Regina Lundrigan, C07D 205/08 (2006.01) Charlestown, MA (US); Eduardo J. A6IP 9/10 (2006.01) Martinez, St. Louis, MO (US); Wayne C. Schairer, Westboro, MA (52) U.S. Cl. .................................... 514/210.02:540/360 (US); John J. Talley, Somerville, MA (US); Timothy C. Barden, Salem, MA (US); Jing Jing Yang, (57) ABSTRACT Boxborough, MA (US); Daniel P. The invention relates to a chemical genus of 4-biphenyl-1- Zimmer, Somerville, MA (US) phenylaZetidin-2-ones useful in the treatment of hypercho Correspondence Address: lesterolemia and other disorders. The compounds have the HESLN ROTHENBERG EARLEY & MEST general formula I: PC S COLUMBIA. CIRCLE ALBANY, NY 12203 (US) (73) Assignee: MICROBIA, INC., Cambridge, MA (US) “O O (21) Appl. No.: 11/913,461 o R2 R4 X (22) PCT Filed: May 5, 2006 R \ / (86). PCT No.: PCT/USO6/17412 S371 (c)(1), (2), (4) Date: May 30, 2008 * / Related U.S. Application Data (60) Provisional application No. 60/677,976, filed on May Pharmaceutical compositions and methods for treating cho 5, 2005. lesterol- and lipid-associated diseases are also disclosed. US 2009/013 1395 A1 May 21, 2009 BPHENYLAZETIONONE CHOLESTEROL autoimmune disorders, (6) an agent used to treat demylena ABSORPTION INHIBITORS tion and its associated disorders, (7) an agent used to treat Alzheimer's disease, (8) a blood modifier, (9) a hormone FIELD OF THE INVENTION replacement agent/composition, (10) a chemotherapeutic 0001.
    [Show full text]
  • Mitigating the Inhibition of Human Bile Salt Export Pump by Drugs
    DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 DMD FastThis Forward. article has not Published been copyedited on andSeptember formatted. The 7, final 2012 version as doi:10.1124/dmd.112.047068may differ from this version. DMD #47968 Mitigating the inhibition of human Bile Salt Export Pump by drugs: opportunities provided by physicochemical property modulation, in-silico modeling and structural modification Daniel J. Warner, Hongming Chen, Louis-David Cantin, J. Gerry Kenna, Simone Stahl, Clare L. Walker, Tobias Noeske. Department of Medicinal Chemistry, AstraZeneca R&D Montreal, Montreal, Quebec, H4S Downloaded from 1Z9, Canada (DJW, LDC) Computational Sciences, Discovery Sciences, AstraZeneca R&D Mölndal, Pepparedsleden dmd.aspetjournals.org 1, Mölndal 43183, Sweden (HC) Molecular Toxicology, Global Safety Assessment, AstraZeneca, Alderley Park, Macclesfield, Cheshire, SK10 4TG, UK (JGK, SS, CLW) Global Safety Assessment, AstraZeneca R&D Mölndal, Pepparedsleden 1, Mölndal 43183, at ASPET Journals on October 10, 2021 Sweden (TN) 1 Copyright 2012 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on September 7, 2012 as DOI: 10.1124/dmd.112.047068 This article has not been copyedited and formatted. The final version may differ from this version. DMD #47968 Inhibition of the human Bile Salt Export Pump by drugs. Corresponding author: Tobias Noeske Global Safety Assessment AstraZeneca R&D Mölndal S-431 83 Mölndal, Sweden Phone: +46-31-7064002 Mobile: +46-727-158344
    [Show full text]
  • Effects of Platelet-Modifying Drugs on Arterial Thromboembolism in Baboons
    Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition. S R Hanson, … , L A Harker, T D Bjornsson J Clin Invest. 1985;75(5):1591-1599. https://doi.org/10.1172/JCI111865. Research Article To resolve questions of drug actions, efficacy, and interactions for platelet-modifying agents used clinically, we have compared the relative capacities and mechanisms of aspirin, dipyridamole, sulfinpyrazone, and dazoxiben to prevent arterial thromboembolism in a baboon model. In 136 studies the agents were given twice daily by oral administration both singly and in combination. The antithrombotic efficacy of a given therapy was determined by its capacity to interrupt steady-state platelet utilization induced by thrombogenic arteriovenous cannulae. When given alone, dipyridamole and sulfinpyrazone reduced the rate at which platelets were utilized by thrombus formation in a dose-dependent manner with essentially complete interruption by dipyridamole at 10 mg/kg per d. In contrast, neither aspirin (2-100 mg/kg per d) nor dazoxiben (20-100 mg/kg per d) decreased cannula platelet consumption detectably despite the striking reduction in the capacity of platelets to produce thromboxane B2. However, aspirin, but not dazoxiben, potentiated the antithrombotic effects of dipyridamole and sulfinpyrazone in a dose-dependent fashion without changing the pharmacokinetics for any of the agents. Complete
    [Show full text]